The β-lactam class of antibiotics, which inhibit the bacterial D,D transpeptidases involved in cell wall biosynthesis, have never been used systematically in the treatment of Mycobacterium tuberculosis infections because of this organism's resistance to β-lactams. The critical resistance factor is the constitutive production of a chromosomally encoded, Ambler class A β-lactamase, BlaC in M. tuberculosis. We show that BlaC is an extended spectrum β-lactamase (ESBL) with high levels of penicillinase and cephalosporinase activity as well as measurable activity with carbapenems, including imipenem and meropenem. We have characterized the enzyme's inhibition by three FDAapproved β-lactamase inhibitors: sulbactam, tazobactam and clavulanate. Sulbactam inhibits the enzyme competitively and reversibly with respect to nitrocefin. Tazobactam inhibits the enzyme in a time-dependent manner, but the activity of the enzyme reappears due to the slow hydrolysis of the covalently acylated enzyme. In contrast, clavulanate reacts with the enzyme quickly to form hydrolytically stable, inactive forms of the enzyme that have been characterized by mass spectrometry. Clavulanate has potential to be used in combination with approved β-lactam antibiotics to treat multi-drug resistant (MDR) and extremely-drug resistant (XDR) strains of Mycobacterium tuberculosis.
demonstrating that the organism is resistant to these antibiotics 9 . Modern chemotherapy of tuberculosis instead relies on the six-month co-administration of four compounds: isoniazid, rifampicin, ethambutol and pyrazinamide. However, β-lactams, alone or in combination with β-lactamase inhibitors, have been shown to be effective in vitro, and in mice and humans infected with M. tuberculosis 10-14 . The low permeability of mycobacterial cell wall towards hydrophilic molecules, as well as the nature of the mycobacterial peptidoglycan were thought to be additional causes of β-lactam resistance in M. tuberculosis 15, 16 . However, Chambers et al., measured permeability coefficients for a number of cephalosporins and penicillins and showed these compounds to be rapidly transported through the outer cell wall of M. tuberculosis H37Ra, at rates comparable to those observed for Pseudomonas aeruginosa 10 .
More recent studies have shown that the intrinsic β-lactam resistance of M. tuberculosis is primarily due to the production of an Ambler class-A β-lactamase encoded by the blaC gene. When blaC is deleted, the strain becomes significantly more susceptible (16-32 fold) towards penicillins as well as third generation cephalosporins and carbapenems 9 . BlaC was initially characterized with regard to its substrate-activity profile 10 years ago 17 and its threedimensional crystal structure was reported last year 18 . However, its inhibition by FDAapproved β-lactamase inhibitors and its spectrum of substrate specificity have not been thoroughly examined. We described here the activity of BlaC, which is an unusual chromosomally encoded, extended spectrum β-lactamase, which hydrolyzes penicillins, cephalosporins and, surprisingly, carbapenems. A detailed analysis of sulbactam, tazobactam and clavulanate using a combination of kinetic studies and mass spectrometry were used to establish their mechanism of inhibition. The results suggest a therapeutic strategy for the treatment of drug-resistant tuberculosis.
METHODS

Production and purification of BlaC
The blaC gene was amplified from genomic DNA and cloned into pET28 using NdeI and HindIII. BlaC was expressed as an N-terminally truncated form, lacking the first 40 amino acids, as previously described 18 . The plasmid was sequenced and transformed into BL21 (DE3) and cultured in LB broth at 37°C. Induction was performed by the addition of IPTG at 16°C for 12 hours. Cells were harvested, resuspended in 25 mM Tris-HCl, containing 300 mM NaCl, pH 7.5 and disrupted by sonication. After centrifugation, the soluble extract was loaded onto a Ni-NTA agarose column (Qiagen) and eluted with 200 mM imidazole in 25 mM TrisHCl, containing 300 mM NaCl, pH 7.5. The eluted fractions were dialyzed against 25 mM Tris-HCl, containing 300 mM NaCl, pH 7.5 to remove the imidazole and thrombin was added to cleave the His 6 N-terminal tag. Size exclusion chromatography was performed using a Superdex 200 Hi-Load 26-60 column (Amersham Pharmacia Biotech) using 25 mM Tris-HCl, containing 300 mM NaCl, pH 7.5 as buffer.
Kinetics
The steady state rate of hydrolysis of the β-lactam ring was monitored as a decrease in the absorbance in the UV region, as previously described 19 . Assays using the chromogenic cephalosporins, CENTA (a gift from R. Pratt, Wesleyan University) and nitrocefin (Beckton Dickinson) were performed at 405 nm (ε = 6,400 M -1 cm -1 ) and 486 nm (ε = 20,500 M -1 cm -1 ), respectively. Assays were performed in 100 mM MES, pH 6.4. Reactions were initiated by the addition of enzyme at a concentration varying from 1.7 nM to 0.3 μM, depending on the substrate used. Initial velocity kinetic data were fit to: (1) Where v is the initial velocity, V is the maximal velocity, and K is the Michaelis constant for the substrate, S.
Inhibition studies
Clavulanate and tazobactam (Sigma) and Sulbactam (LKT laboratories) were used at concentrations ranging from 0 to 70 μM, using ca. 0.2 nM of BlaC and 100 μM nitrocefin in 100 mM MES, pH 6.4. Time courses were followed for 10 min. For slow-onset inhibition, reaction velocities as a function of time were fitted to eq 2, where [P] is the concentration of product, v i and v s are the initial and final velocities of the reaction in the presence of inhibitor, k iso is the apparent first-order rate constant for the interconversion between v i and v s , and t is time. (2) We have used the classical model for such inhibition, which includes the rapid binding of I to the enzyme to form the EI complex, followed by a slower isomerization of the complex to form the EI* complex.
Using this model, the rate constants that describe k iso are given by eq (3), where
For tazobactam, showing a non zero intercept value for k iso vs [tazobactam], K i * was calculated using eq (4): (4) For reversible competitive inhibition, velocities were fitted to the equation (5) The analysis of the recovery of β-lactamase activity was performed by incubating the enzyme (20 μM) with the three β-lactamase inhibitors (100 μM) in 100 mM MES, pH 6.4. Initial velocities were measured at different times using a final concentration of 0.8 nM enzyme in 100 mM MES, pH 6.4 and 200 μM nitrocefin.
Mass spectrometry
All mass spectra were acquired on a 9.4 Tesla fourier transform ion cyclotron resonance (FTICR) mass spectrometer (Ionspec, Lake Forest, CA). To avoid salt interference, BlaC was dialyzed and concentrated in 10 mM MES, pH 6.4 to a concentration of 200μM. The stock solution was diluted to 20μM and inhibitors were added at a final concentration of 100 μM. 10 pmoles of enzyme were directly injected onto a C18 column at 10μL/min in 50% acetonitrile containing 0.1% TFA. The molecular mass of each protein sample was determined for the 25 + charge state using the equation m=((m/z)*25)-25 on the isotopic centroid.
BlaC was expressed in E. coli cells and purified in two steps, essentially as previously described 18 . Size exclusion chromatography shows that BlaC elutes at a position expected for the monomer in solution, and the purity was >95% according to Coomassie staining. The overall yield was 125 mg/L of culture.
Substrate specificity
Initial rate kinetics were used to determined the steady-state kinetic parameters for a wide variety of substrates at pH 6.4 (Table 1 ). BlaC exhibits extraordinarily broad substrate specificity, with high k cat values for both penicillins and cephalosporins. For penicillins, especially ampicillin, the k cat /K m values are close to 10 8 M -1 min -1 , values that suggest that the enzyme operates with these substrates at the diffusion-limited rate. The k cat /K m values observed for the cephalosporins range from ca. 10 7 -10 4 M -1 min -1 . As the enzyme can also hydrolyze second and third generation cephalosporins (cefuroxime, cefamandole, cefoxitin, ceftazidime, ceftriaxone, cefotaxime), this enzyme is a naturally occurring, chromosomally encoded extended spectrum β-lactamase (ESBL). In general, ESBLs are derivatives of β-lactamases that have acquired mutations after antibiotic exposure 20 , which is clearly not the case for the M. tuberculosis BlaC or the β-lactamase recently described from Mycobacterium fortuitum 21 . Perhaps most surprisingly, BlaC is capable of hydrolyzing both imipenem, and to a lesser extent, meropenem. Usually the carbapenems, such as meropenem, are potent inhibitors of Ambler class A β-lactamases. It has been suggested that the 6(7)α position occupied by bulky groups in penem β-lactams interact with a conserved asparagine residue (Asn132) of the SDN motif of penicillin binding proteins and β-lactamases 22 . This residue is a glycine residue in BlaC, and this substitution is likely to be responsible for the carbapenemase activity, as it is unique among class A β-lactamases 23 .
Inhibition by β-lactamase inhibitors
We investigated the inhibition patterns of the FDA approved β-lactamase inhibitors clavulanate, tazobactam and sulbactam. Sulbactam displayed classical, linear competitive inhibition versus nitrocefin, inhibiting the enzyme with a K i value of 0.70 ± 0.05 μM. Both tazobactam and clavulanate inhibited BlaC in a time-dependent manner, reminiscent of slowonset inhibition (Figure 2 ). When time courses were fit to eq 2 and the determined values of k iso are plotted against [tazobactam] (Fig. 2B) , a non-zero intercept is observed. This requires that the E-I ↔ E-I* isomerization is reversible and allows the values of K i and K i * to be calculated to be 7.5 ± 0.8 μM and 0.34 ± 0.12 μM, respectively. The values of k 2 and k -2 were determined from the value of k iso at [tazobactam] = O and [tazobactam] = ∞. These values were determined to be k 2 = 0.38 ± 0.01 min -1 and k -2 = 0.018 ± 0.004 min -1 for tazobactam. In contrast, using clavulanate the plot of k iso vs.
[clavulanate] reveals an intercept value that cannot be distinguished from zero ( Fig. 2A) . This suggests that once the E-clavulanate* complex is formed, it cannot go back to the E-clavulanate complex, making the step irreversible. The K i value for clavulanate is 12.1 μM and k 2 is 1.6 ± 0.04 min -1 . The K i value determined here is slightly higher from the one reported by Wang et al 18 , who reported the inhibition to be biphasic.
In order to identify the acyl-enzyme forms of the sulbactam, tazobactam and clavulanate inhibited enzyme species (i.e., E-I and E-I*), we used Fourier transform ion cyclotron resonance (FTICR) mass spectrometry to follow the covalent modification of the enzyme at times after the addition of the inhibitors. The calculated mass of the free enzyme is 27784.481, and the experimental mass is 28784.475. Using tazobactam, the mass spectrum reveals that the enzyme is covalently modified within 5 minutes and exists in two major forms: one with the entire tazobactam molecule bound (Enz+300.95, predicted +300.29) and a second with an increment of mass 69.95 ( Figure S1 ). This latter complex is presumably the propionaldehyde ester (+70.06) that has been previously observed after enzyme acylation and inhibitor fragmentation with penicillin sulfones 24 . However, within 12 min of mixing BlaC with tazobactam, peaks in the mass spectrum corresponding to the free enzyme appear, and after 45 minutes, the acylated forms have completely disappeared. Full activity was recovered after 45 minutes suggesting that the enzyme was slowly hydrolyzing the acylated enzyme serine residue (S70) ( Figure S1 ). Similarly for sulbactam, we found that covalent adducts could be observed immediately upon mixing with BlaC and, as with tazobactam, two peaks corresponding to the mass of the E-inhibitor complex (Enz+233.40, predicted +233.24) as well as the aldehyde (Enz +69.57). However, these complexes were rapidly hydrolyzed and within 30 minutes, the mass spectrum revealed only the native, unmodified enzyme form ( Figure S2 ), and full activity was recovered (Figure 4) . The fact that sulbactam does not show slow-onset inhibition likely reflects the very rapid isomerization rate with sulbactam compared to tazobactam.
Within three minutes of the addition of clavulanate, three peaks are observed in the mass spectrum, none of which is the intact BlaC-clavulanate covalent adduct (Fig 3, predicted E clavulanate = 27784.481 + 199.16). The lowest molecular weight adduct is the enzymepropionaldehyde form (Fig 3, peak A ; Enz +70.22) observed with tazobactam and sulbactam. The other two forms appear at Enz+136.27 (Fig 3, peak B ) and Enz+154.40 (Fig 3, peak C) . One of these other two forms correspond to the enzyme adduct of clavulanate after decarboxylation (Enz+154.40) to generate an imine (or enamine tautomer) form of inhibitor 25-27 . The other minor component (peak B) is most likely a covalent adduct in which the imine undergoes the additional loss of a water molecule (Enz + 136.12). These latter forms are likely to be stable to hydrolysis, since no BlaC activity can be detected after incubation with clavulanate for 60 minutes (Figure 4) , and even after 12 hours (data not shown). The small amount of propionaldehyde adduct is likely to be slowly hydrolyzed by BlaC, since this same adduct is generated by all three β-lactamase inhibitors. It is likely to be continuously generated until all of the enzyme is present in the non-hydrolyzable complexes represented by Peaks B and C. Alternatively, clavulanate might uniquely lead to the covalent modification of S130, as has been proposed for clavulanate inhibition of other β-lactamases 28 .
We propose a mechanism for the inhibition of BlaC by clavulanate based on these mass spectrometry results (Fig 5) . Once the catalytic serine residue reacts with the β-lactam ring of clavulanate, causing the rupture of the β-lactam bond, the remaining ring is ruptured to generate the acyclic imine form of the enzyme-bound complex. This intermediate is rapidly decarboxylated due to the presence of the ketone adjacent to the carboxyl group that can stabilize the carbanion generated by decarboxylation. This is the form of the adduct that predominates (ca. 70%) after prolonged incubation of BlaC with clavulanate (Fig 5, compound  C) . While we show this in Figure 5 as the trans-C 3 -N 4 imine tautomer, the C2-C3 eneamine and N4-C5-imine tautomers can presumably also occur, and these would reduce the propensity for hydrolysis. Small amounts of a covalent adduct formed by the dehydration of compound A to generate compound B are observed, and this dehydration chemistry has not previously been reported. The imine of compound C can be hydrolyzed to generate the propionaldehyde ester that is also the product of the tazobactam and sulbactam reactions (Fig 5, compound A) . This propionaldehyde covalent adduct is presumably unstable and is hydrolyzed since it is also formed transiently with tazobactam and sulbactam. Only clavulanate leads to the stable inactivation of the enzyme and we therefore propose that the inactive forms of the enzyme are compounds C and B in Figure 5 .
DISCUSSION
Tazobactam and sulbactam, members of the penicilline sulfone family of β-lactamase inhibitors inhibit BlaC, but the covalent adduct generated is unstable and is hydrolyzed, whereas clavulanate leads to the stable inactivation of the enzyme. Since 1983, there have been episodic reports of the in vitro and in vivo efficacy of combination β-lactam/ β-lactamase inhibitor therapy for M. tuberculosis infections. One of the first of these showed that the combination of amoxicillin and clavulanate was bactericidal in vitro against 14 of 15 M. tuberculosis isolates tested 13 . All penicillins, cephalosporins and imipenem tested have very high affinity for the M. tuberculosis H37Ra penicillin binding proteins, and although inactive on their own, the MIC value of amoxicillin can be reduced from >16 to 0.5 μg/ml by the coadministration with clavulanate 10 . The combination of amoxicillin and clavulanate has also been used clinically in the treatment of tuberculosis patients, including those harboring multidrug resistant strains, and shown to have early bactericidal activity comparable to other drugs used to treat tuberculosis with the exception of isoniazid 11,14 . The results presented here clarify the kinetic and mechanistic differences between the various β-lactamase inhibitors and reveal that clavulanate is unique amongst the β-lactamase inhibitors is being able to stably inhibit BlaC. A combination of clavulanate and a β-lactam, perhaps imipenem which has recently been shown to have activity on its own in the treatment of human and murine tuberculosis 12 , should be explored in the treatment of currently untreatable multidrug and extremely-drug resistant 1 M. tuberculosis infections. Enzyme (20 μM) was incubated with 100 μM sulbactam (▲), 100 μM tazobactam (■) or 100 μM clavulanate (•), and activity was determined at the indicated times. After acylation of the clavulanate molecule, rearrangement and decarboxylation lead to the imine (C), which undergoes loss of a water molecule (B), or hydrolysis to form the propionaldehyde (A).
